Philippines CSDT Dossier Structure: Format, Scope and Review Logic

1. Key takeaways

The CSDT (Common Submission Dossier Template) is the technical file format for medical device registration agreed by the ten ASEAN member states and developed by the ACCSQ-MDPWG (ASEAN Consultative Committee on Standards and Quality — Medical Device Product Working Group). In the Philippines, CMDR applications for Class B, C and D devices must be submitted in CSDT format, while Class A devices follow the shorter CMDN notification document list.

GRZAN note: the CSDT governs how information is arranged, not whether the information is good enough. A dossier that is formally perfect in CSDT structure but thin on evidence is still a deficient dossier. The framework can be remembered as 1 template, 2 submission pathways, and 3 gates that decide the outcome: format compliance, module completeness, and substantive content quality.

• CSDT is the common ASEAN dossier format, developed by ACCSQ-MDPWG;
• Class B, C and D devices file CMDR applications in CSDT structure;
• Class A devices file the shorter CMDN notification list;
• The Abridged pathway under FC No. 2022-008 requires filing in AMDD-CSDT format.

The practical consequence is that the CSDT is not a document produced once at the end of a project, but a container that has to be filled module by module while the underlying evidence is still being generated. Companies that treat it as a formatting exercise at the finish line usually discover their gaps at the moment when fixing them is most expensive.

2. Legal basis

The instrument that adopts the CSDT in the Philippines, together with its scope and the conditions attached to the fast-track route, is summarised below. The framework has a regional origin and a national implementation: the format itself is an ASEAN harmonisation product that integrates GHTF global technical requirements, while the obligation to use it derives from the Philippine administrative order.

3. Expert insights

Insight 1: the value of the CSDT is one preparation serving many markets, but reuse is not copying. The greatest benefit of the template is regional portability: a single skeleton can be reused across several ASEAN markets. What differs between countries is the version, the annex requirements, the module order and the local additions. The workable structure is a master CSDT plus country-specific difference packs kept separately and assembled at submission. The master file carries the common skeleton; each country pack carries its own deviations, so the dossier can be reused without being rejected for formatting reasons.

Insight 2: the CSDT is a format requirement, not a content exemption. Many companies assume that writing to the CSDT format is itself compliance. In fact the template solves a different problem: it lets a reviewer find information efficiently. It prescribes the organisation of information and does not lower any technical threshold. Every module inside it still has a substantive gate — the essential principles checklist must be argued point by point, design verification and validation must be supported by test data, risk management must conform to ISO 14971, and clinical evidence must support the intended use as declared. Reviewers read the same file twice for two different purposes: once to confirm that the structure is right, and once to test whether the content inside that structure survives scrutiny. Passing the first reading says nothing about the second.

Insight 3: the completeness of the CSDT directly determines the timeline. Review at the CDRRHR is modular. A gap in any single module triggers a deficiency notice, and every deficiency cycle pushes the overall schedule back. A workable internal quality control method is module-by-module closure: review each module once it is finished rather than stacking everything for a single check at the end. Closing modules as they complete prevents the discovery of systemic problems at the final stage, when remediation means reworking the whole file.

Insight 4: the CSDT and the Abridged pathway are bound together. One of the preconditions of FC No. 2022-008 is that the application is filed in AMDD-CSDT format. This means that even where a product is already approved in another ASEAN member state, the fast track is unavailable if the original submission was not made in CSDT format. For companies planning several ASEAN markets, the signal is strong: start with the CSDT in the first market, and later markets retain the possibility of acceleration.

4. Practical recommendations

• Build a master CSDT plus country difference packs. Manage the common skeleton and the local deviations separately so that neither contaminates the other.
• Close modules one at a time. Review each module independently as it completes rather than accumulating work for a final sweep.
• Keep a documented version history. Record what changed in each CSDT revision and when, so that differences can be explained when the same file is reused in another market.
• File in CSDT format from the first ASEAN market. This preserves Abridged eligibility for subsequent submissions.

These four habits address the same underlying risk from different angles: the risk that formatting work is mistaken for substantive work, and that gaps surface only after the file has been filed. A master-and-packs structure keeps reuse honest, module-by-module closure keeps gaps local, version history keeps multi-country submissions explainable, and early CSDT adoption keeps the fast track open. None of them is expensive to set up at the start of a project; all of them are expensive to retrofit once a deficiency notice has already been issued and the schedule has begun to slip.

5. Verification checklist

• □ Applicable pathway and format confirmed: B/C/D to CSDT, A to the notification list
• □ Current CSDT version confirmed with the FDA website or the CDRRHR
• □ Module completeness verified against a module-by-module checklist
• □ Administrative documents assembled: application form, copy of the LTO, LOA, proof of payment
• □ Technical file assembled: device description, essential principles, verification and validation, risk management, clinical evidence
• □ Labels and instructions for use in English with all elements present
• □ Non-English documents accompanied by certified English translations

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including the Philippines. Our team prepares CMDN/CMDR dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with the FDA Philippines, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com